Avricore Health (AVCRF) Cash & Equivalents (2013 - 2025)

Avricore Health (AVCRF) has 13 years of Cash & Equivalents data on file, last reported at $812022.8 in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $812022.8, up 310.15% year-over-year; the trailing twelve-month figure through Dec 2025 was $812022.8 (up 310.15% YoY), and the FY2025 annual result was $810477.2, up 301.21% from the prior year.
• Cash & Equivalents grew to $812022.8 in Q4 2025 per AVCRF's latest filing, from $386389.6 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $2.0 million in Q1 2021 and troughed at $197983.1 in Q4 2024.
• A 5-year average of $816081.0 and a median of $540035.7 in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents jumped 6079.41% in 2021, then slumped 71.37% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $1.6 million in 2021, then tumbled by 71.37% to $457144.1 in 2022, then decreased by 0.29% to $455799.1 in 2023, then slumped by 56.56% to $197983.1 in 2024, then jumped by 310.15% to $812022.8 in 2025.
• Business Quant data shows AVCRF's Cash & Equivalents at $812022.8 in Q4 2025, $386389.6 in Q3 2025, and $617201.3 in Q2 2025.